Although glucagon typically raises blood sugar, in the presence of GLP-1 and GIP, the response becomes more balanced, leading to: increased energy expenditure enhanced fat oxidation greater metabolic burn at rest reduction in liver fat prevention of metabolic slowdown during weight loss This combination makes retatrutide particularly effective for individuals who typically plateau on GLP-1 drugs due to metabolic adaptation
MeAgain is the better fit for GLP-1 users who want food, shots, symptoms, hydration, weight, progress, and medication context to live together
It is a network of regions that decide what feels important, what gets repeated, and what becomes a habit
Both companies were driven by the same purpose and selling the same product, yet two distinct internal cultures and approaches were developed
Interestingly, appendicular BMD, but not axial BMD, was not reduced despite significant weight loss in the semaglutide group and no changes in BTMs or bone microarchitecture was encountered [70]